Indication
Netherton Syndrome
8 clinical trials
9 products
Product
DS-2325aClinical trial
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton SyndromeStatus: Recruiting, Estimated PCD: 2024-06-01
Product
SpesolimabClinical trial
EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton SyndromeStatus: Recruiting, Estimated PCD: 2024-12-30
Product
QRX003Clinical trial
A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton SyndromeStatus: Recruiting, Estimated PCD: 2024-12-30
Product
QRX003-2%Product
QRX003-4%Clinical trial
A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton SyndromeStatus: Recruiting, Estimated PCD: 2025-01-31
Product
VehicleClinical trial
A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-05-11
Product
PlaceboProduct
ATR12-351Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton SyndromeStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-01-26
Clinical trial
A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton SyndromeStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Dupilumab